Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.44 |
| ▸ | CKS1B | P61024 | 3/20 | 0.44 |
| ▸ | SKP1 | P63208 | 3/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | ACACA | Q13085 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985736 | 0.93 | IGF1R (0.41) | PRMT5CKS1BSKP1SKP2IGF1R | |
| SCHEMBL210610 | 0.89 | MEN1 (0.43) | TNKSTNKS2MEN1KMT2A | |
| SCHEMBL208496 | 0.89 | PRMT5 (0.44) | PRMT5CKS1BSKP1SKP2IGF1R | |
| SCHEMBL16152488 | 0.87 | MEN1 (0.38) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL13985468 | 0.84 | AURKA (0.41) | PRMT5CKS1BSKP1SKP2IGF1R | |
| SCHEMBL211207 | 0.82 | AURKA (0.53) | IGF1R | |
| SCHEMBL210746 | 0.81 | AURKA (0.41) | PRMT5MEN1KMT2ALMNA | |
| SCHEMBL13985470 | 0.81 | AURKA (0.44) | — | |
| SCHEMBL208759 | 0.79 | CHEK2 (0.40) | PRMT5TNKSTNKS2 | |
| SCHEMBL13985592 | 0.79 | TBK1 (0.42) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | PRMT5 312/4885CKS1B 28/4885SKP1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.